Skip to content

Study · Randomized controlled trial · n = 62 · 2004

4 results

Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial.

Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, Crowe BJ, Ross JL, Cassorla FG, Blum WF, Cutler GB Jr, Baron J

The Journal of clinical endocrinology and metabolism1 Jul 2004Cited by 145 (Europe PMC)

PMID15240584 (opens in a new tab)DOI10.1210/jc.2003-031457 (opens in a new tab)PepBankPUB-15240584
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with idiopathic short stature, modified intent-to-treat analysis showed a GH benefit on last observed height of 0.52 SDS (3.8 cm; P < 0.001; 95% CI 0.22-0.82 SDS).

    In plain wordsIn children with idiopathic short stature, growth hormone improved last observed height by 3.8 cm versus placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLast observed height SDS
    Study

    n = 62

    Comparator
    placebo
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    0.074 mg/kg three times per week · subcutaneous · at least 6 monthsAs given in this study (human).

    Measurements

    Difference in last observed height SDS
    0.52 SDS
    GH versus placebo, modified intent-to-treat, 62 patients
    Difference in last observed height
    3.8 cm
    GH versus placebo, modified intent-to-treat, 62 patients
    95% confidence interval, last observed height SDS difference
    0.22 to 0.82 SDS
    GH versus placebo
    P value
    < 0.001 P value
    last observed height SDS, GH versus placebo

    Source sentences

    Summary
    Modified intent-to-treat analysis in 62 patients treated for at least 6 months indicated a similar GH effect on last observed height SDS (0.52 SDS; 3.8 cm; P < 0.001; 95% confidence interval, 0.22-0.82 SDS) and no important dropout bias.
    2 context sentences
    Summary · context
    We performed a randomized, double-blind, placebo-controlled trial to determine the effect of GH on adult height in peripubertal children.
    Summary · context
    Subjects (n = 68; 53 males and 15 females), 9-16 yr old, with marked, idiopathic short stature [height or predicted height < or = -2.5 sd score (SDS)] received either GH (0.074 mg/kg) or placebo sc three times per week until they were near adult height.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with idiopathic short stature, adult height was -1.81 +/- 0.11 versus -2.32 +/- 0.17 SDS with placebo, a 0.51 SDS benefit (3.7 cm; P < 0.02; 95% CI 0.10-0.92 SDS).

    In plain wordsIn children with idiopathic short stature, growth hormone increased adult height by 3.7 cm versus placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseAdult height
    Study

    n = 33

    Comparator
    placebo
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    0.074 mg/kg three times per week · subcutaneous · mean 4.4 yrAs given in this study (human).

    Measurements

    Adult height, GH-treated (least squares mean, +/- sem 0.11)
    −1.81 SDS
    33 patients with adult height
    Adult height, placebo-treated (least squares mean, +/- sem 0.17)
    −2.32 SDS
    33 patients with adult height
    Adult height difference, GH vs placebo
    0.51 SDS
    33 patients with adult height
    Adult height difference, GH vs placebo
    3.7 cm
    33 patients with adult height
    95% confidence interval for adult height difference
    0.1 to 0.92 SDS
    GH vs placebo
    P value
    < 0.02 P
    GH vs placebo adult height

    Source sentences

    Summary
    Adult height was greater in the GH-treated group (-1.81 +/- 0.11 SDS, least squares mean +/- sem) than in the placebo-treated group (-2.32 +/- 0.17 SDS) by 0.51 SDS (3.7 cm; P < 0.02; 95% confidence interval, 0.10-0.92 SDS).
    3 context sentences
    Summary · context
    At study termination, adult height measurements were available for 33 patients after mean treatment duration of 4.4 yr.
    Summary · context
    We performed a randomized, double-blind, placebo-controlled trial to determine the effect of GH on adult height in peripubertal children.
    Summary · context
    Subjects (n = 68; 53 males and 15 females), 9-16 yr old, with marked, idiopathic short stature [height or predicted height < or = -2.5 sd score (SDS)] received either GH (0.074 mg/kg) or placebo sc three times per week until they were near adult height.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In children with idiopathic short stature, growth hormone improved adult height minus baseline height SDS versus placebo.

    In plain wordsIn children with idiopathic short stature, growth hormone improved height gain from baseline versus placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseAdult height minus baseline height SDS
    Study

    n = 33

    Comparator
    placebo
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    0.074 mg/kg three times per week · subcutaneous · mean 4.4 yrAs given in this study (human).

    Source sentences

    Summary
    A similar GH effect was demonstrated in terms of adult height SDS minus baseline height SDS and adult height SDS minus baseline predicted height SDS.
    2 context sentences
    Summary · context
    We performed a randomized, double-blind, placebo-controlled trial to determine the effect of GH on adult height in peripubertal children.
    Summary · context
    Subjects (n = 68; 53 males and 15 females), 9-16 yr old, with marked, idiopathic short stature [height or predicted height < or = -2.5 sd score (SDS)] received either GH (0.074 mg/kg) or placebo sc three times per week until they were near adult height.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In children with idiopathic short stature, growth hormone improved adult height minus baseline predicted height SDS versus placebo.

    In plain wordsIn children with idiopathic short stature, growth hormone improved adult height relative to baseline predicted height versus placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseAdult height SDS minus baseline predicted height SDS
    Study

    n = 33

    Comparator
    placebo
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    0.074 mg/kg three times per week · subcutaneous · mean 4.4 yrAs given in this study (human).

    Source sentences

    Summary
    A similar GH effect was demonstrated in terms of adult height SDS minus baseline height SDS and adult height SDS minus baseline predicted height SDS.
    2 context sentences
    Summary · context
    We performed a randomized, double-blind, placebo-controlled trial to determine the effect of GH on adult height in peripubertal children.
    Summary · context
    Subjects (n = 68; 53 males and 15 females), 9-16 yr old, with marked, idiopathic short stature [height or predicted height < or = -2.5 sd score (SDS)] received either GH (0.074 mg/kg) or placebo sc three times per week until they were near adult height.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.